OverviewSuggest Edit

We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical companies. We have built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. We have an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. ... Show more
TypePublic
Founded1996
HQBurnaby, CA
Websitexenon-pharma.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Feb 2019)77
Job Openings8
Revenue (FY, 2017)$311 K(-82%)
Share Price (Feb 2019)$8.1 (+4%)

Xenon Pharmaceuticals Office Locations

Xenon Pharmaceuticals has an office in Burnaby
Burnaby, CA (HQ)
3650 Gilmore Way
Show all (1)
Report incorrect company information

Xenon Pharmaceuticals Financials and Metrics

Xenon Pharmaceuticals Revenue

Xenon Pharmaceuticals's revenue was reported to be $311 k in FY, 2017
USD

Net income (Q3, 2018)

(12.8m)

EBIT (Q3, 2018)

(14.2m)

Market capitalization (15-Feb-2019)

203.9m

Closing stock price (15-Feb-2019)

8.1

Cash (30-Sep-2018)

88.0m
Xenon Pharmaceuticals's current market capitalization is $203.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

15.6mwdxefcqufszuzezftuxetqsqxt1.8m311.0k

General and administrative expense

9.8m6.8m7.3m

R&D expense

15.2m19.8m25.6m

Operating expense total

24.9m26.6m32.9m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

4.0m4.3m601.0k413.0k413.0k16.0k15.0k264.0k

General and administrative expense

1.6m2.1m1.3m1.9m1.7m1.8m2.1m1.8m1.7m2.2m2.2m1.9m

R&D expense

3.4m3.7m3.8m4.4m5.1m6.0m5.9m6.1m7.2m5.6m5.4m6.2m

Operating expense total

10.1m3.8m5.1m6.3m6.8m7.7m8.0m7.9m8.9m7.8m7.6m14.2m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

58.7m17.1m20.5m

Accounts Receivable

315.0k200.0k438.0k

Current Assets

60.9m65.7m44.8m

PP&E

2.0m1.4m1.1m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(15.8m)(23.0m)(30.7m)

Depreciation and Amortization

1.0m864.0k649.0k

Accounts Payable

80.0k547.0k(3.0k)

Cash From Operating Activities

(18.1m)(19.6m)(28.7m)
Show all financial metrics
Report incorrect company information

Xenon Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Xenon Pharmaceuticals News and Updates

Xenon Pharmaceuticals Outlines 2019 Key Milestones

Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019

Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

BURNABY, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Stifel 2018 Healthcare Conference in N…

Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development

Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares

BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,500,000 common shares pursuant to its existing shelf registrat…

Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registrat…

Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Novel Epilepsy Product Candidates – XEN1101 and XEN901 – Continue to Advance in the Clinic
Show more
Report incorrect company information

Xenon Pharmaceuticals Company Life and Culture

Report incorrect company information

Xenon Pharmaceuticals Frequently Asked Questions

  • When was Xenon Pharmaceuticals founded?

    Xenon Pharmaceuticals was founded in 1996.

  • How many employees does Xenon Pharmaceuticals have?

    Xenon Pharmaceuticals has 77 employees.

  • What is Xenon Pharmaceuticals revenue?

    Latest Xenon Pharmaceuticals annual revenue is $311 k.

  • What is Xenon Pharmaceuticals revenue per employee?

    Latest Xenon Pharmaceuticals revenue per employee is $4 k.

  • Who are Xenon Pharmaceuticals competitors?

    Competitors of Xenon Pharmaceuticals include Cipan, Iterum Therapeutics and Spotlight Innovation.

  • Where is Xenon Pharmaceuticals headquarters?

    Xenon Pharmaceuticals headquarters is located at 3650 Gilmore Way, Burnaby.

  • Where are Xenon Pharmaceuticals offices?

    Xenon Pharmaceuticals has an office in Burnaby.

  • How many offices does Xenon Pharmaceuticals have?

    Xenon Pharmaceuticals has 1 office.